Join Clinical Trials
  • Login
  • Home
  • Clinical Trial Categories
  • Adults - 18 - 64
  • Florida
  • Orlando


Menu

Choose Which Database to Search - Volunteer Database - Clinical Trial Database Create an Account - VOLUNTEER Accounts - RECRUITER Accounts Account Login - Volunteers Login - Recruiters Login Join a Clinical Trial Clinical Trials by Category Clinical Trials by Location Submit a Clinical Trial Frequently Asked Questions Contact Us Sitemap Blog

Categories

    Healthy Volunteers Adults - 18 - 64 Youths - Birth - 17 Seniors - 65 + Expanded Access Compensated Trials Clinical Trials by Condition Trials by Drug Type Trials for Rare Conditions

Recent Listings

  • Post your clinical trial on JoinClinicalTrials.com

    Ellijay, Georgia 30536
    United States

    Post your clinical trial on JoinClinicalTrials.com

    05-09-2019 01:01PM

JoinClinicalTrials.com




Results

Post your clinical trial on JoinClinicalTrials.com
Hot

Post your clinical trial on JoinClinicalTrials.com


Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

Results 1 - 1 of 1
  • <<
  • <
  • 1
  • >
  • >>

  • A Trial to Evaluate the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder
    NCT03605836
    Conditions:   Attention Deficit Disorder;   Attention Deficit Hyperactivity Disorder
    Interventions:   Drug: Centanafadine SR;   Other: Placebo
    Sponsor:   Otsuka Pharmaceutical Development & Commercialization, Inc.
    Recruiting
  • 2 New Measurements Used to Describe the Filling Phase of the Left Ventricle (LV).
    NCT04154878
    Conditions:   Diastolic Heart Failure;   Left Ventricular Diastolic Dysfunction;   Left Ventricular Diastolic Collapse
    Intervention:  
    Sponsor:   Florida Hospital
    Recruiting
  • A Pharmacokinetic Study of Padsevonil in Study Participants With Either Normal or Moderately Impaired Hepatic Function
    NCT04136444
    Conditions:   Healthy Study Participants;   Impaired Hepatic Function
    Intervention:   Drug: Padsevonil
    Sponsor:   UCB Biopharma S.P.R.L.
    Recruiting
  • Fine Needle Biopsy of Solid Pancreatic Mass Lesions
    NCT04085055
    Condition:   Solid Tumor
    Intervention:   Diagnostic Test: Solid pancreatic mass lesion biopsy
    Sponsor:   Florida Hospital
    Recruiting
  • Renal PK Study of LC350189
    NCT04066712
    Conditions:   Gout;   Hyperuricemia
    Intervention:   Drug: LC350189 200 mg
    Sponsor:   LG Chem
    Recruiting
  • Duodenoscope Assessment Tool Development
    NCT04004533
    Condition:   Endoscopy
    Intervention:   Procedure: endoscopy
    Sponsor:   Florida Hospital
    Recruiting
  • Endoscopic Ultrasound vs Percutaneous Route for Biopsy
    NCT04003766
    Condition:   Liver Biopsy
    Intervention:   Diagnostic Test: biopsy
    Sponsor:   Florida Hospital
    Recruiting
  • Radiation Exposure Assessment in Fluoroscopy
    NCT03985488
    Conditions:   Fluoroscopy; Adverse Effect;   Radiation Exposure
    Intervention:   Radiation: Radiation exposure
    Sponsor:   Florida Hospital
    Recruiting
  • CharacterIzation of Adult Onset Autoimmune Diabetes
    NCT03971955
    Condition:   Diabetes
    Interventions:   Other: Mixed Meal Test;   Other: Dual Energy X-Ray Absorptiometry (DEXA);   Procedure: Adipose Tissue Biopsy
    Sponsor:   Translational Research Institute for Metabolism and Diabetes, Florida
    Recruiting
  • Safety and Efficacy Study of AB002 (E-WE Thrombin) in End Stage Renal Disease Patients on Chronic Hemodialysis
    NCT03963895
    Conditions:   End Stage Renal Disease;   Thrombosis
    Interventions:   Drug: AB002;   Drug: placebo
    Sponsors:   Aronora, Inc.;   Celerion
    Recruiting
  • The Role of Microbiome Reprogramming on Liver Fat Accumulation
    NCT03914495
    Condition:   NAFLD
    Interventions:   Dietary Supplement: Inulin;   Dietary Supplement: Placebo
    Sponsor:   Translational Research Institute for Metabolism and Diabetes, Florida
    Recruiting
  • Exploration of Patient Ethics and Communication Excellence (PEACE) Rounds
    NCT03874676
    Condition:   Resilience
    Intervention:   Other: PEACE Rounds
    Sponsor:   Florida Hospital
    Recruiting
  • Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)
    NCT03713684
    Condition:   Type 2 Diabetes Mellitus
    Interventions:   Drug: Efpeglenatide SAR439977;   Drug: Placebo;   Drug: Insulin glargine
    Sponsor:   Sanofi
    Recruiting
  • Investigating the Effects of Mikei® Red Reishi Essence EX on the Immune System of Prostate Cancer Patients and Patients With Non-cancerous Conditions of the Prostate
    NCT03589781
    Condition:   Prostate Cancer
    Interventions:   Dietary Supplement: Mikei Red Reishi Essence EX;   Dietary Supplement: Placebo
    Sponsor:   Nikkei (Canada) Marketing Limited
    Recruiting
  • Study Assessing PK and Safety of MGTA-145 in Subjects With Normal Estimated GFR and Varying Degrees of Renal Impairment
    NCT04154670
    Conditions:   Healthy;   Renal Insufficiency
    Intervention:   Biological: MGTA-145
    Sponsor:   Magenta Therapeutics, Inc.
    Recruiting
  • Safety and Pharmacokinetics of Linzagolix in Female Subjects With Normal and Impaired Renal Function
    NCT03961932
    Conditions:   Renal Impairment;   Healthy Participants
    Intervention:   Drug: Linzagolix
    Sponsor:   ObsEva SA
    Recruiting
  • Safety and Pharmacokinetics of MK-2060 in Older Participants With End-Stage Renal Disease on Hemodialysis (MK-2060-004)
    NCT03873038
    Conditions:   Renal Dialysis;   Kidney Failure, Chronic
    Interventions:   Drug: MK-2060;   Drug: Placebo
    Sponsor:   Merck Sharp & Dohme Corp.
    Recruiting
  • Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC)
    NCT03014648
    Condition:   Advanced Non-small Cell Lung Cancer
    Intervention:   Drug: Atezolizumab
    Sponsors:   Liza Villaruz, MD;   Genentech, Inc.
    Recruiting
  • Safety and Pharmacokinetics Study of Linzagolix in Female Subjects With Normal and Impaired Hepatic Function
    NCT03962049
    Conditions:   Hepatic Impairment;   Healthy Participants
    Intervention:   Drug: Linzagolix
    Sponsor:   ObsEva SA
    Recruiting
  • Study to Evaluate DNL747 in Subjects With Amyotrophic Lateral Sclerosis
    NCT03757351
    Condition:   Amyotrophic Lateral Sclerosis
    Interventions:   Drug: DNL747;   Drug: Placebo
    Sponsor:   Denali Therapeutics Inc.
    Recruiting
  • Pharmacogenetics Sampling of the CC-90007-CP-003 Study Cohort
    NCT04097704
    Condition:   Hepatic Insufficiency
    Intervention:  
    Sponsor:   Celgene
    Recruiting
  • A Study of Tirzepatide in Participants With Impaired Liver Function
    NCT03940742
    Condition:   Hepatic Insufficiency
    Intervention:   Drug: Tirzepatide
    Sponsor:   Eli Lilly and Company
    Recruiting
  • A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics and Safety and Tolerability of a Single Oral Dose of Risdiplam Compared to Matched Healthy Participants With Normal Hepatic Function
    NCT03920865
    Condition:   Muscular Atrophy, Spinal
    Intervention:   Drug: Risdiplam
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab
    NCT03856099
    Condition:   Recurrent Glioblastoma
    Intervention:   Drug: TTAC-0001
    Sponsor:   PharmAbcine
    Recruiting
  • Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's Disease
    NCT03611569
    Conditions:   Healthy;   Parkinson Disease
    Interventions:   Drug: Lu AF82422;   Drug: Placebo
    Sponsor:   H. Lundbeck A/S
    Recruiting
  • Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme
    NCT02465268
    Conditions:   Glioblastoma Multiforme;   Glioblastoma;   Malignant Glioma;   Astrocytoma, Grade IV;   GBM
    Interventions:   Biological: pp65-shLAMP DC with GM-CSF;   Biological: unpulsed PBMC and saline;   Drug: Td;   Drug: Saline;   Biological: pp65-flLAMP DC with GM-CSF
    Sponsors:   University of Florida;   National Cancer Institute (NCI)
    Recruiting
  • Effect Of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of PF-06865571 In Subjects With Hepatic Impairment and in Healthy Subjects
    NCT04091061
    Conditions:   Hepatic Impairment;   Healthy Volunteers
    Intervention:   Drug: PF-06865571 100 mg
    Sponsor:   Pfizer
    Recruiting
  • A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of PF-06651600 in Subjects With Hepatic Impairment and Healthy Volunteers
    NCT04016077
    Conditions:   Hepatic Impairment;   Healthy Participants
    Intervention:   Drug: PF-06651600 30 mg
    Sponsor:   Pfizer
    Recruiting
  • A Pharmacokinetic Study of Omaveloxolone in Subjects With Hepatic Impairment and Normal Hepatic Function
    NCT03902002
    Condition:   Hepatic Impairment
    Intervention:   Drug: Omaveloxolone 50 mg capsules
    Sponsor:   Reata Pharmaceuticals, Inc.
    Recruiting
  • ACES - ACE Inhibitors Combined With Exercise for Seniors With Hypertension
    NCT03295734
    Conditions:   Hypertension;   Aging;   Sedentary Lifestyle
    Interventions:   Behavioral: Aerobic exercise;   Drug: Perindopril;   Drug: Losartan;   Drug: HCTZ
    Sponsors:   University of Alabama at Birmingham;   University of Colorado, Denver;   Translational Research Institute for Metabolism and Diabetes, Advent Health
    Recruiting
  • Pharmacokinetics of MB-102 and Use of the Non-invasive Optical Renal Function Monitor (ORFM) Device in Subjects With Normal and Impaired Renal Function and a Range of Skin Color Types
    NCT02772276
    Condition:   Acute Kidney Injury
    Interventions:   Drug: MB-102;   Drug: Iohexol;   Device: QuantumLeap;   Device: Radiance;   Device: Brilliance
    Sponsor:   MediBeacon
    Recruiting
  • To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD8233 After Multiple Dose Administration in Subjects With Type 2 Diabetes.
    NCT04155645
    Conditions:   Dyslipidemia;   Type 2 Diabetes
    Interventions:   Drug: AZD8233 subcutaneous injection;   Drug: Placebo
    Sponsors:   AstraZeneca;   Parexel
    Recruiting
  • A Phase 3 Study to Confirm the Efficacy and Safety of Linzagolix to Treat Endometriosis-associated Pain
    NCT03986944
    Condition:   Endometriosis
    Interventions:   Drug: Placebo linzagolix tablets and Placebo Add-back capsule;   Drug: Placebo linzagolix and linzagolix tablets and Placebo Add-back capsule;   Drug: Placebo linzagolix and linzagolix tablets and Add-back capsule
    Sponsor:   ObsEva SA
    Recruiting
  • Biospecimen Analysis in Determining Effects of Chemotherapy on Fertility in Osteosarcoma Survivors
    NCT03206450
    Conditions:   Cancer Survivor;   Osteosarcoma
    Interventions:   Procedure: Biospecimen Collection;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Spanish Intervention for Caregivers of Veterans With Stroke
    NCT03142841
    Condition:   Depression
    Intervention:   Other: RESCUE Problem Solving Intervention
    Sponsor:   VA Office of Research and Development
    Recruiting
  • A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
    NCT01848561
    Condition:   Ulcerative Colitis (UC)
    Intervention:  
    Sponsor:   AbbVie
    Recruiting
  • Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide
    NCT00632853
    Condition:   Lung Cancer
    Interventions:   Radiation: Standard Radiation Dose Therapy;   Drug: cisplatin;   Drug: etoposide;   Radiation: High Radiation Dose Therapy;   Drug: carboplatin
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting
  • A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause
    NCT04003389
    Condition:   Hot Flashes
    Interventions:   Drug: fezolinetant;   Drug: placebo
    Sponsor:   Astellas Pharma Global Development, Inc.
    Recruiting
  • A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause
    NCT04003155
    Condition:   Hot Flashes
    Interventions:   Drug: fezolinetant;   Drug: placebo
    Sponsor:   Astellas Pharma Global Development, Inc.
    Recruiting
  • Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers
    NCT03768414
    Conditions:   Stage III Distal Bile Duct Cancer AJCC v8;   Stage III Gallbladder Cancer AJCC v8;   Stage III Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IIIA Distal Bile Duct Cancer AJCC v8;   Stage IIIA Gallbladder Cancer AJCC v8;   Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IIIB Distal Bile Duct Cancer AJCC v8;   Stage IIIB Gallbladder Cancer AJCC v8;   Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IV Distal Bile Duct Cancer AJCC v8;   Stage IV Gallbladder Cancer AJCC v8;   Stage IV Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IVA Gallbladder Cancer AJCC v8;   Stage IVB Gallbladder Cancer AJCC v8;   Unresectable Extrahepatic Bile Duct Carcinoma;   Unresectable Gallbladder Carcinoma;   Unresectable Intrahepatic Cholangiocarcinoma
    Interventions:   Drug: Cisplatin;   Drug: Gemcitabine Hydrochloride;   Drug: Nab-paclitaxel
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
    NCT03414970
    Conditions:   Ductal Breast Carcinoma;   Invasive Breast Carcinoma;   Lobular Breast Carcinoma;   Medullary Breast Carcinoma;   Stage II Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Tubular Breast Carcinoma
    Interventions:   Radiation: Radiation Therapy;   Other: Questionnaire Administration;   Other: Quality-of-Life Assessment;   Other: Laboratory Biomarker Analysis;   Radiation: Hypofractionated Radiation Therapy
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Canadian Cancer Trials Group
    Recruiting
  • Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
    NCT03233711
    Conditions:   Anal Basaloid Carcinoma;   Anal Canal Cloacogenic Carcinoma;   Anal Margin Squamous Cell Carcinoma;   Stage IIB Anal Cancer AJCC v8;   Stage IIIA Anal Cancer AJCC v8;   Stage IIIB Anal Cancer AJCC v8;   Stage IIIC Anal Cancer AJCC v8
    Interventions:   Biological: Nivolumab;   Other: Patient Observation
    Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
    Recruiting
  • AURORA: Phase 3 Study for the Efficacy and Safety of CVC for the Treatment of Liver Fibrosis in Adults With NASH
    NCT03028740
    Condition:   Nonalcoholic Steatohepatitis
    Interventions:   Drug: Cenicriviroc;   Drug: Placebo
    Sponsor:   Tobira Therapeutics, Inc.
    Recruiting
  • Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis
    NCT02958865
    Condition:   Ulcerative Colitis
    Interventions:   Drug: PF-06651600 or Placebo;   Drug: PF-06700841 or Placebo;   Drug: PF-06700841;   Drug: PF-06651600
    Sponsor:   Pfizer
    Recruiting
  • Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
    NCT02194738
    Conditions:   Lung Adenocarcinoma;   Lung Large Cell Carcinoma;   Resectable Lung Non-Small Cell Carcinoma;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IB Lung Squamous Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage II Lung Squamous Cell Carcinoma AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIA Lung Squamous Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Squamous Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7;   Stage IIIA Lung Squamous Cell Carcinoma AJCC v7
    Interventions:   Other: Clinical Observation;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Erlotinib;   Drug: Erlotinib Hydrochloride;   Biological: Nivolumab;   Other: Placebo
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
    NCT02193282
    Conditions:   EGFR Exon 19 Deletion Mutation;   EGFR NP_005219.2:p.L858R;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7
    Interventions:   Other: Clinical Observation;   Drug: Erlotinib;   Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Placebo
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • A Study to Determine the Outcomes of Patients With Localized B Cell Lymphoblastic Lymphoma (B-LLy) When Treated With Standard Risk B-ALL Therapy
    NCT03914625
    Conditions:   B Acute Lymphoblastic Leukemia;   B Lymphoblastic Lymphoma;   Down Syndrome
    Interventions:   Drug: Asparaginase Erwinia chrysanthemi;   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Leucovorin;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Mercaptopurine Oral Suspension;   Drug: Methotrexate;   Drug: Prednisolone;   Drug: Prednisone;   Drug: Thioguanine;   Drug: Vincristine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations
    NCT03581292
    Conditions:   Anaplastic Astrocytoma;   Glioblastoma;   Malignant Glioma
    Interventions:   Radiation: Radiation Therapy;   Drug: Temozolomide;   Drug: Veliparib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
    NCT03233204
    Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Low Grade Glioma;   Malignant Glioma;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Ependymoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Childhood Malignant Germ Cell Tumor;   Refractory Ependymoma;   Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Glioma;   Refractory Malignant Solid Neoplasm;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma;   Rhabdoid Tumor;   Wilms Tumor
    Intervention:   Drug: Olaparib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
    NCT03220035
    Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Ependymoma;   Ewing Sarcoma;   Hepatoblastoma;   Langerhans Cell Histiocytosis;   Malignant Germ Cell Tumor;   Malignant Glioma;   Osteosarcoma;   Peripheral Primitive Neuroectodermal Tumor;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Refractory Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Rhabdoid Tumor;   Rhabdomyosarcoma;   Soft Tissue Sarcoma;   Wilms Tumor
    Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Vemurafenib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
    NCT03213704
    Conditions:   Advanced Malignant Solid Neoplasm;   Recurrent Ependymoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Glioma;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Rhabdoid Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Ependymoma;   Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Glioma;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Wilms Tumor
    Interventions:   Drug: Larotrectinib;   Drug: Larotrectinib Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
    NCT03213678
    Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Non-Hodgkin Lymphoma;   Malignant Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Rhabdoid Tumor;   Stage III Osteosarcoma AJCC v7;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Osteosarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Stage IVA Osteosarcoma AJCC v7;   Stage IVB Osteosarcoma AJCC v7;   Wilms Tumor
    Interventions:   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Samotolisib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
    NCT03213665
    Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Hodgkin Lymphoma;   Ann Arbor Stage III Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Hodgkin Lymphoma;   Ann Arbor Stage IV Non-Hodgkin Lymphoma;   Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   EZH2 Gene Mutation;   Low Grade Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Hodgkin Lymphoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Glioma;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdoid Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Hodgkin Lymphoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Glioma;   Refractory Malignant Solid Neoplasm;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Peripheral Primitive Neuroectodermal Tumor;   Refractory Rhabdoid Tumor;   Refractory Soft Tissue Sarcoma;   Rhabdoid Tumor;   SMARCA4 Gene Inactivation;   SMARCB1 Gene Inactivation;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Wilms Tumor
    Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Tazemetostat
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
    NCT03213652
    Conditions:   Advanced Malignant Solid Neoplasm;   ALK Fusion Protein Expression;   ALK Gene Mutation;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Refractory Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   ROS1 Fusion Positive;   ROS1 Gene Mutation
    Interventions:   Drug: Ensartinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
    NCT03210714
    Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Low Grade Glioma;   Malignant Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Childhood Ependymoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Rhabdoid Tumor;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Wilms Tumor
    Interventions:   Drug: Erdafitinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
    NCT03155620
    Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Non-Hodgkin Lymphoma;   Histiocytic Sarcoma;   Juvenile Xanthogranuloma;   Langerhans Cell Histiocytosis;   Malignant Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdoid Tumor;   Recurrent Soft Tissue Sarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Ewing Sarcoma;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Solid Neoplasm;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Peripheral Primitive Neuroectodermal Tumor;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Rhabdoid Tumor;   Stage III Osteosarcoma AJCC v7;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Osteosarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Stage IVA Osteosarcoma AJCC v7;   Stage IVB Osteosarcoma AJCC v7;   Wilms Tumor
    Interventions:   Procedure: Biopsy;   Procedure: Biospecimen Collection;   Drug: Ensartinib;   Drug: Erdafitinib;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Procedure: Mutation Carrier Screening;   Drug: Olaparib;   Drug: Palbociclib;   Other: Pharmacological Study;   Drug: Samotolisib;   Drug: Selumetinib Sulfate;   Drug: Tazemetostat;   Drug: Ulixertinib;   Drug: Vemurafenib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
    NCT03067181
    Conditions:   Childhood Extracranial Germ Cell Tumor;   Extragonadal Embryonal Carcinoma;   Germ Cell Tumor;   Malignant Germ Cell Tumor;   Malignant Ovarian Teratoma;   Stage I Ovarian Choriocarcinoma;   Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage I Ovarian Teratoma AJCC v6 and v7;   Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage I Testicular Choriocarcinoma AJCC v6 and v7;   Stage I Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage I Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage II Ovarian Choriocarcinoma;   Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage II Testicular Choriocarcinoma AJCC v6 and v7;   Stage II Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage II Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage III Ovarian Choriocarcinoma;   Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage III Testicular Choriocarcinoma AJCC v6 and v7;   Stage III Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage III Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage IV Ovarian Choriocarcinoma;   Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7;   Testicular Mixed Choriocarcinoma and Embryonal Carcinoma;   Testicular Mixed Choriocarcinoma and Teratoma;   Testicular Mixed Choriocarcinoma and Yolk Sac Tumor
    Interventions:   Other: Best Practice;   Drug: Bleomycin;   Biological: Bleomycin Sulfate;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Etoposide;   Drug: Etoposide Phosphate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Late Effects After Treatment in Patients With Previously Diagnosed High-Risk Neuroblastoma
    NCT03057626
    Conditions:   Recurrent Neuroblastoma;   Stage 2A Neuroblastoma;   Stage 2B Neuroblastoma;   Stage 3 Neuroblastoma;   Stage 4 Neuroblastoma;   Stage 4S Neuroblastoma
    Interventions:   Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
    NCT03007147
    Conditions:   B Acute Lymphoblastic Leukemia;   BCR-ABL1 Fusion Protein Expression;   Minimal Residual Disease;   Philadelphia Chromosome Positive;   T Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Dexrazoxane Hydrochloride;   Drug: Doxorubicin;   Drug: Etoposide;   Biological: Filgrastim;   Drug: Ifosfamide;   Drug: Imatinib Mesylate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Methylprednisolone;   Drug: Pegaspargase;   Drug: Prednisolone;   Other: Questionnaire Administration;   Drug: Therapeutic Hydrocortisone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI);   University of Milano Bicocca
    Recruiting
  • Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
    NCT02867592
    Conditions:   Adrenal Cortex Carcinoma;   Alveolar Soft Part Sarcoma;   Central Nervous System Neoplasm;   Childhood Clear Cell Sarcoma of Soft Parts;   Clear Cell Sarcoma of Soft Tissue;   Ewing Sarcoma;   Hepatoblastoma;   Hepatocellular Carcinoma;   Osteosarcoma;   Recurrent Adrenal Cortex Carcinoma;   Recurrent Alveolar Soft Part Sarcoma;   Recurrent Ewing Sarcoma;   Recurrent Hepatoblastoma;   Recurrent Hepatocellular Carcinoma;   Recurrent Malignant Central Nervous System Neoplasm;   Recurrent Malignant Solid Neoplasm;   Recurrent Osteosarcoma;   Recurrent Renal Cell Carcinoma;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Recurrent Thyroid Gland Medullary Carcinoma;   Refractory Ewing Sarcoma;   Refractory Malignant Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Osteosarcoma;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma;   Renal Cell Carcinoma;   Rhabdomyosarcoma;   Solid Neoplasm;   Thyroid Gland Medullary Carcinoma;   Wilms Tumor
    Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma
    NCT02724579
    Conditions:   CTNNB1 Gene Mutation;   Medulloblastoma;   Wnt Positive
    Interventions:   Drug: Cisplatin;   Drug: Cyclophosphamide;   Other: Laboratory Biomarker Analysis;   Drug: Lomustine;   Radiation: Radiation Therapy;   Drug: Vincristine;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
    NCT02567435
    Conditions:   Alveolar Rhabdomyosarcoma;   Botryoid-Type Embryonal Rhabdomyosarcoma;   Embryonal Rhabdomyosarcoma;   Rhabdomyosarcoma;   Sclerosing Rhabdomyosarcoma;   Spindle Cell Rhabdomyosarcoma
    Interventions:   Drug: Cyclophosphamide;   Biological: Dactinomycin;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration;   Radiation: Radiation Therapy;   Drug: Temsirolimus;   Drug: Vincristine Sulfate;   Drug: Vinorelbine
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia.
    NCT04072835
    Condition:   Paroxysmal Supraventricular Tachycardia
    Intervention:   Drug: Etripamil NS
    Sponsors:   Milestone Pharmaceuticals Inc.;   IQVIA Biotech
    Recruiting
  • A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD
    NCT03953079
    Condition:   Neovascular Age-Related Macular Degeneration
    Interventions:   Drug: Drug: GB-102;   Drug: Aflibercept
    Sponsor:   Graybug Vision
    Recruiting
  • Clostridium Difficile Vaccine 2-Dose Versus 3-Dose Study
    NCT03918629
    Condition:   Clostridium Difficile Associated Disease
    Interventions:   Biological: Clostridium difficile;   Biological: Placebo
    Sponsor:   Pfizer
    Recruiting
  • A Study to Compare the Efficacy of SEL-212 to KRYSTEXXA® in Gout Patients Refractory to Conventional Therapy
    NCT03905512
    Condition:   Chronic Gout
    Interventions:   Drug: SEL-212;   Drug: SEL-037;   Drug: SEL-110;   Drug: KRYSTEXXA®
    Sponsor:   Selecta Biosciences, Inc.
    Recruiting
  • Florida Pancreas Collaborative Next Generation Biobank
    NCT03851133
    Conditions:   Pancreatic Cancer;   Cancer Cachexia
    Interventions:   Other: Blood Sample Collection;   Other: Tumor Sample collection;   Other: Data Collection
    Sponsor:   H. Lee Moffitt Cancer Center and Research Institute
    Recruiting
  • Durvalumab vs Placebo Following Stereotactic Body Radiation Therapy in Early Stage Non-small Cell Lung Cancer Patients
    NCT03833154
    Condition:   Carcinoma, Non-Small-Cell Lung
    Interventions:   Drug: Durvalumab;   Other: Placebo
    Sponsor:   AstraZeneca
    Recruiting
  • Safety and Effectiveness Evaluation of the Multi-Electrode Radiofrequency Balloon Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation
    NCT03683030
    Condition:   Atrial Fibrillation
    Intervention:   Device: Radiofrequency Ablation
    Sponsor:   Biosense Webster, Inc.
    Recruiting
  • A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis.
    NCT03682705
    Condition:   Rheumatoid Arthritis (RA)
    Interventions:   Drug: Upadacitinib;   Drug: ABBV-105;   Drug: Upadacitinib placebo;   Drug: ABBV-105 placebo
    Sponsor:   AbbVie
    Recruiting
  • A Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
    NCT03675308
    Condition:   Psoriatic Arthritis
    Interventions:   Biological: placebo for rizankizumab;   Biological: risankizumab
    Sponsor:   AbbVie
    Recruiting
  • A Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)
    NCT03671148
    Condition:   Psoriatic Arthritis
    Interventions:   Biological: placebo for rizankizumab;   Biological: risankizumab
    Sponsor:   AbbVie
    Recruiting
  • An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease
    NCT03599622
    Conditions:   Granulomatous Colitis;   Crohn's Disease;   Crohn's Enteritis;   Granulomatous Enteritis
    Interventions:   Drug: BMS-986165;   Other: Placebo
    Sponsor:   Bristol-Myers Squibb
    Recruiting
  • A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis
    NCT03524092
    Condition:   Ulcerative Colitis
    Interventions:   Drug: Mirikizumab;   Drug: Placebo
    Sponsor:   Eli Lilly and Company
    Recruiting
  • An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
    NCT03518086
    Condition:   Ulcerative Colitis
    Interventions:   Drug: Mirikizumab;   Drug: Placebo
    Sponsor:   Eli Lilly and Company
    Recruiting
  • Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF‑06700841 In Subjects With Moderate To Severe Crohn's Disease
    NCT03395184
    Condition:   Crohn's Disease
    Interventions:   Drug: Placebo PF-06651600;   Drug: Placebo PF-06700841;   Drug: PF-06651600;   Drug: PF-06700841
    Sponsor:   Pfizer
    Recruiting
  • Hemodynamic-GUIDEd Management of Heart Failure
    NCT03387813
    Conditions:   Heart Failure;   Heart Failure, Systolic;   Heart Failure, Diastolic;   Heart Failure NYHA Class II;   Heart Failure NYHA Class III;   Heart Failure NYHA Class IV;   Heart Failure,Congestive;   Heart Failure With Reduced Ejection Fraction;   Heart Failure With Normal Ejection Fraction;   Heart Failure; With Decompensation
    Intervention:   Device: CardioMEMS™ HF System
    Sponsor:   Abbott Medical Devices
    Recruiting
  • Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis
    NCT03350815
    Condition:   Ankylosing Spondylitis
    Interventions:   Drug: 150 mg open-label secukinumab;   Drug: 150 mg double-blinded secukinumab;   Drug: 300 mg double-blinded secukinumab
    Sponsor:   Novartis Pharmaceuticals
    Recruiting
  • A Study of the Efficacy and Safety of Upadacitnib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies
    NCT03345849
    Condition:   Crohn's Disease
    Interventions:   Drug: Upadacitinib;   Drug: Placebo for Upadacitinib
    Sponsor:   AbbVie
    Recruiting
  • A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy
    NCT03345836
    Condition:   Crohn's Disease
    Interventions:   Other: Matching placebo for upadacitinib;   Drug: upadacitinib
    Sponsor:   AbbVie
    Recruiting
  • DRCR.Net Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DME
    NCT03321513
    Condition:   Diabetic Macular Edema
    Interventions:   Drug: intravitreous aflibercept;   Drug: Bevacizumab + Deferred Aflibercept Group
    Sponsor:   Jaeb Center for Health Research
    Recruiting
  • QP ExCELs: MultiPole Pacing (MPP) Sub-Study
    NCT03155724
    Condition:   Heart Failure
    Intervention:   Device: MultiPole Pacing
    Sponsor:   Biotronik, Inc.
    Recruiting
  • Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The ECLIPSE Trial
    NCT03108456
    Conditions:   Coronary Artery Disease;   Ischemic Heart Disease;   Non ST Segment Elevation Myocardial Infarction
    Interventions:   Device: Orbital Atherectomy;   Device: Balloon
    Sponsors:   Cardiovascular Systems Inc;   Cardiovascular Research Foundation, New York
    Recruiting
  • MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
    NCT03072927
    Condition:   Lumbar Spinal Stenosis
    Intervention:   Device: MILD
    Sponsor:   Vertos Medical, Inc.
    Recruiting
  • ADAPT - A Patient Registry of the Real-world Use of Orenitram®
    NCT03045029
    Condition:   Pulmonary Arterial Hypertension
    Intervention:   Drug: Oral treprostinil
    Sponsor:   United Therapeutics
    Recruiting
  • A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)
    NCT02998528
    Condition:   Non Small Cell Lung Cancer
    Interventions:   Biological: Nivolumab;   Drug: Cisplatin;   Drug: Vinorelbine;   Drug: Gemcitabine;   Drug: Docetaxel;   Drug: Pemetrexed;   Drug: Carboplatin;   Drug: Paclitaxel;   Biological: Ipilimumab
    Sponsors:   Bristol-Myers Squibb;   Ono Pharmaceutical Co. Ltd
    Recruiting
  • Patient Empowered Strategy to Reduce Asthma Morbidity in Highly Impacted Populations; PeRson EmPowered Asthma RElief
    NCT02995733
    Condition:   Asthma
    Intervention:   Drug: PARTICS using QVAR
    Sponsors:   Brigham and Women's Hospital;   Patient-Centered Outcomes Research Institute;   American Academy of Family Physicians
    Recruiting
  • Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH)
    NCT02855164
    Condition:   Non-alcoholic Steatohepatitis (NASH)
    Interventions:   Drug: Tropifexor (LJN452);   Drug: Placebo
    Sponsor:   Novartis Pharmaceuticals
    Recruiting
  • A Study to Evaluate the Efficacy and Safety of TF0023 Spray on Subjects With Ischemic Strokes
    NCT02785120
    Condition:   Ischemic Stroke
    Intervention:   Drug: TF0023
    Sponsor:   Techfields Inc
    Recruiting
  • A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression
    NCT02782104
    Condition:   Depressive Disorder, Treatment-Resistant
    Intervention:   Drug: Esketamine Nasal Spray
    Sponsor:   Janssen Research & Development, LLC
    Recruiting
  • Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE
    NCT02630316
    Conditions:   Pulmonary Hypertension;   Interstitial Lung Disease;   Combined Pulmonary Fibrosis and Emphysema
    Interventions:   Drug: Inhaled Treprostinil;   Drug: Placebo
    Sponsor:   United Therapeutics
    Recruiting
  • A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
    NCT02565511
    Condition:   Alzheimer's Disease
    Interventions:   Biological: CAD106 Immunotherapy;   Other: Placebo to CAD106;   Drug: CNP520;   Other: Placebo to CNP520
    Sponsors:   Novartis Pharmaceuticals;   Banner Alzheimer's Institute;   National Institute on Aging (NIA);   Alzheimer's Association;   Amgen
    Recruiting
  • Sentus QP - Extended CRT Evaluation With Quadripolar Left Ventricular Leads
    NCT02290028
    Condition:   Heart Failure
    Intervention:   Device: Sentus QP left ventricular lead
    Sponsors:   Biotronik SE & Co. KG;   Biotronik, Inc.
    Recruiting
  • Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery
    NCT03533582
    Conditions:   Childhood Hepatocellular Carcinoma;   Childhood Malignant Liver Neoplasm;   Hepatoblastoma;   Hepatocellular Malignant Neoplasm, Not Otherwise Specified;   SMARCB1 Gene Mutation
    Interventions:   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Fluorouracil;   Drug: Gemcitabine;   Drug: Irinotecan;   Other: Laboratory Biomarker Analysis;   Drug: Oxaliplatin;   Other: Patient Observation;   Drug: Sorafenib;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
    NCT03526250
    Conditions:   Advanced Malignant Solid Neoplasm;   Recurrent Childhood Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Kidney Wilms Tumor;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Glioma;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdoid Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Ependymoma;   Refractory Ewing Sarcoma;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Glioma;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Peripheral Primitive Neuroectodermal Tumor;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Palbociclib;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis
    NCT01885078
    Condition:   Rheumatoid Arthritis
    Interventions:   Drug: Baricitinib;   Drug: Placebo
    Sponsor:   Eli Lilly and Company
    Recruiting
  • Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery
    NCT01872975
    Conditions:   Stage IB Breast Cancer;   Stage II Breast Cancer
    Interventions:   Radiation: regional nodal XRT;   Radiation: chestwall XRT;   Radiation: WBI
    Sponsors:   NSABP Foundation Inc;   National Cancer Institute (NCI);   Radiation Therapy Oncology Group
    Recruiting
  • A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome
    NCT03355209
    Condition:   Lennox Gastaut Syndrome
    Interventions:   Drug: ZX008 0.2 or 0.8 mg/kg/day;   Drug: Matching Placebo
    Sponsor:   Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
    Recruiting
  • Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma
    NCT03126916
    Conditions:   Ganglioneuroblastoma;   INRG Stage L2;   INRG Stage M;   INRG Stage MS;   Neuroblastoma;   NMYC Gene Amplification;   Recurrent Neuroblastoma
    Interventions:   Biological: Aldesleukin;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Crizotinib;   Drug: Cyclophosphamide;   Drug: Dexrazoxane Hydrochloride;   Biological: Dinutuximab;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide Phosphate;   Radiation: External Beam Radiation Therapy;   Radiation: Iobenguane I-131;   Drug: Isotretinoin;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Other: Pharmacological Study;   Biological: Sargramostim;   Procedure: Therapeutic Conventional Surgery;   Drug: Thiotepa;   Drug: Topotecan Hydrochloride;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
    NCT02723994
    Condition:   Leukemia
    Interventions:   Drug: Ruxolitinib;   Drug: Asparaginase Erwinia Chrysanthemi;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
    Sponsors:   Incyte Corporation;   Children's Oncology Group
    Recruiting
  • Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
    NCT03653091
    Condition:   Type 2 Diabetes
    Interventions:   Device: Duodenal Mucosal Resurfacing (DMR);   Device: Duodenal Mucosal Resurfacing Sham (Sham)
    Sponsor:   Fractyl Laboratories, Inc.
    Recruiting
  • A Phase I Study for Safety and Tolerability of AL002.
    NCT03635047
    Conditions:   Healthy;   Alzheimer Disease
    Interventions:   Biological: AL002;   Other: Saline Solution
    Sponsor:   Alector Inc.
    Recruiting
  • Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Patients With Schizophrenia
    NCT03593213
    Condition:   Schizophrenia
    Interventions:   Drug: Cariprazine;   Drug: Placebo
    Sponsor:   Forest Laboratories
    Recruiting
  • A Study to Explore the Efficacy of JNJ-67953964 in the Treatment of Depression
    NCT03559192
    Condition:   Depressive Disorder, Major
    Interventions:   Drug: JNJ-67953964;   Drug: Placebo
    Sponsor:   Janssen Research & Development, LLC
    Recruiting
  • This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months
    NCT03351244
    Condition:   Schizophrenia
    Interventions:   Drug: BI 409306;   Drug: Placebo
    Sponsor:   Boehringer Ingelheim
    Recruiting
  • AMPLATZER PFO Occluder Post Approval Study
    NCT03309332
    Conditions:   Stroke;   Patent Foramen Ovale
    Intervention:   Device: AMPLATZER™ PFO Occluder
    Sponsor:   Abbott Medical Devices
    Recruiting
  • Trial of Inhaled Molgramostim in CF Subjects With NTM Infection
    NCT03597347
    Conditions:   Mycobacterium Infections, Nontuberculous;   Cystic Fibrosis (CF)
    Interventions:   Drug: Molgramostim nebulizer solution;   Device: PARI eFlow nebulizer system
    Sponsor:   Savara Inc.
    Recruiting
  • SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain
    NCT03204318
    Condition:   Endometriosis Related Pain
    Interventions:   Drug: Relugolix;   Drug: Estradiol/norethindrone acetate;   Drug: Placebo for E2/NETA;   Drug: Placebo for relugolix
    Sponsor:   Myovant Sciences GmbH
    Recruiting
  • Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
    NCT03150693
    Condition:   B Acute Lymphoblastic Leukemia
    Interventions:   Drug: Allopurinol;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Vincristine Sulfate;   Drug: Dexamethasone;   Drug: Pegylated L-Asparaginase;   Drug: Methotrexate;   Procedure: Bone Marrow Aspiration and Biopsy;   Drug: Cyclophosphamide;   Drug: Mercaptopurine;   Biological: Rituximab;   Drug: Doxorubicin;   Drug: Thioguanine;   Biological: Inotuzumab Ozogamicin;   Other: Laboratory Biomarker Analysis
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Short-term Clinical Deterioration After Acute Pulmonary Embolism
    NCT03915925
    Condition:   Pulmonary Embolism
    Intervention:  
    Sponsors:   Atrium Health;   Agency for Healthcare Research and Quality (AHRQ)
    Recruiting
  • Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated Donors
    NCT00785525
    Condition:   Healthy
    Intervention:   Drug: Filgrastim
    Sponsors:   Center for International Blood and Marrow Transplant Research;   National Marrow Donor Program
    Recruiting
  • Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
    NCT03422822
    Condition:   Dermatitis, Atopic
    Interventions:   Drug: PF-04965842 100 mg;   Drug: PF-04965842 200 mg;   Drug: Placebo
    Sponsor:   Pfizer
    Recruiting
  • Neuropsychological and Behavioral Testing in Younger Patients With Cancer
    NCT00772200
    Conditions:   Childhood Malignant Neoplasm;   Cognitive Side Effects of Cancer Therapy
    Interventions:   Procedure: Cognitive Assessment;   Other: Quality-of-Life Assessment
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Ulcerative Colitis Who Have Failed Prior Biologic Therapy
    NCT03398148
    Condition:   Ulcerative Colitis (UC)
    Interventions:   Drug: risankizumab IV;   Drug: placebo for risankizumab;   Drug: risankizumab SC
    Sponsor:   AbbVie
    Recruiting
  • A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Ulcerative Colitis Who Responded to Induction Treatment in M16-067 or M16-065
    NCT03398135
    Condition:   Ulcerative Colitis (UC)
    Interventions:   Drug: risankizumab;   Drug: placebo for risankizumab
    Sponsor:   AbbVie
    Recruiting
  • A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications
    NCT03381196
    Condition:   Influenza A
    Interventions:   Drug: Pimodivir 600 mg;   Drug: Placebo;   Other: SOC Treatment
    Sponsor:   Janssen Research & Development, LLC
    Recruiting
  • A Study of AeroVanc for the Treatment of MRSA Infection in CF Patients
    NCT03181932
    Conditions:   MRSA;   Cystic Fibrosis
    Interventions:   Drug: Vancomycin inhalation powder;   Drug: Placebo inhalation powder
    Sponsor:   Savara Inc.
    Recruiting
  • A Randomised Trial of S-ICD Implantation With and Without Defibrillation Testing
    NCT03495297
    Condition:   Ventricular Arrythmia
    Intervention:   Procedure: ommitence of defibrillation testing
    Sponsors:   Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA);   Boston Scientific Corporation
    Recruiting
  • Validation of Software for Assessment of Atrial Fibrillation From Data Acquired by a Wearable Smartwatch
    NCT04176926
    Condition:   Atrial Fibrillation
    Intervention:   Diagnostic Test: Electrocardiogram
    Sponsor:   Fitbit Inc
    Recruiting
  • Axillary Reverse Mapping in Preventing Lymphedema in Patients With Breast Cancer Undergoing Axillary Lymph Node Dissection
    NCT03927027
    Conditions:   Breast Cancer Stage I;   Breast Cancer Stage II;   Breast Cancer Stage III
    Interventions:   Drug: Isosulfan Blue;   Procedure: Axillary Lymph Node Dissection;   Procedure: Mapping;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Pan Tumor Nivolumab Rollover Study
    NCT03899155
    Condition:   Cancer
    Intervention:   Drug: Nivolumab
    Sponsor:   Bristol-Myers Squibb
    Recruiting
  • Heart EXPAND Continued Access Protocol
    NCT03835754
    Condition:   Heart Transplant
    Intervention:   Device: OCS Heart System
    Sponsor:   TransMedics
    Recruiting
  • A Proof of Concept Study of GSK3640254 in Human Immunodeficiency Virus-1 (HIV-1) Infected Treatment-naive Adults
    NCT03784079
    Condition:   HIV Infections
    Interventions:   Drug: GSK3640254;   Drug: Placebo matching GSK3640254 Mesylate salt
    Sponsor:   ViiV Healthcare
    Recruiting
  • Prospective Evaluation of Open Irrigated Ablation Catheters With High Resolution Mapping to Treat Paroxysmal Atrial Fibrillation
    NCT03729830
    Condition:   Paroxysmal Atrial Fibrillation
    Intervention:   Device: Boston Scientific Open Irrigated Ablation Catheters
    Sponsor:   Boston Scientific Corporation
    Recruiting
  • BI 655130 Long-term Treatment in Patients With moderate-to Severe Ulcerative Colitis
    NCT03648541
    Condition:   Colitis, Ulcerative
    Interventions:   Drug: Spesolimab IV infusion;   Drug: Spesolimab SC solution for injection
    Sponsor:   Boehringer Ingelheim
    Recruiting
  • Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease
    NCT03533257
    Condition:   Alzheimer Disease
    Interventions:   Drug: AMX0035;   Drug: Placebo
    Sponsors:   Amylyx Pharmaceuticals Inc.;   Alzheimer’s Drug Discovery Foundation;   Alzheimer's Association
    Recruiting
  • A Study of RO7082859 in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Non-Hodgkin Lymphomas and Participants With DLBCL
    NCT03467373
    Conditions:   B-Cell Lymphoma;   Non-Hodgkin Lymphoma
    Interventions:   Drug: RO7082859;   Drug: Obinutuzumab (G);   Drug: Rituximab (R);   Drug: Tocilizumab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • A Prospective, Multi-Center Evaluation of the ECHELON CIRCULAR Powered Stapler in Left-Sided Colorectal Anastomoses
    NCT03326895
    Condition:   Left-sided Colon Resection
    Intervention:   Device: Left-sided colon resection
    Sponsor:   Ethicon Endo-Surgery
    Recruiting
  • INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections
    NCT03037164
    Condition:   Anemia
    Interventions:   Device: INTERCEPT Blood System for Red Blood Cells;   Device: Conventional (Control)
    Sponsor:   Cerus Corporation
    Recruiting
  • Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
    NCT03018288
    Condition:   Glioblastoma
    Interventions:   Drug: Pembrolizumab;   Biological: HSPPC-96;   Drug: Temozolomide;   Other: Placebo
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Feasibility Study of the Intravascular Ventricular Assist System (iVAS)
    NCT02645539
    Conditions:   Heart Failure NYHA Class III;   Heart Failure NYHA Class IV
    Intervention:   Device: intravascular ventricular assist system (iVAS)
    Sponsor:   NuPulseCV
    Recruiting
  • A Study of YH25448 in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
    NCT04075396
    Condition:   Carcinoma, Non-Small-Cell Lung
    Intervention:   Drug: YH25448
    Sponsors:   Janssen Research & Development, LLC;   Yuhan Corporation
    Recruiting
  • S1803, Daratumumab/rHuPh20 +/- Lenalidomide as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
    NCT04071457
    Condition:   Multiple Myeloma
    Interventions:   Drug: Lenalidomide;   Drug: Daratumumab/rHuPH20
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Janssen, LP;   Adaptive
    Recruiting
  • Molecular Transducers of Physical Activity Consortium
    NCT03960827
    Condition:   Physical Activity
    Interventions:   Other: Endurance Training;   Other: Restistance Training
    Sponsors:   University of Florida;   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   Stanford University;   Broad Institute;   Duke University;   Emory University;   Icahn School of Medicine at Mount Sinai;   Mayo Clinic;   Pacific Northwest National Laboratory;   University of Michigan;   Wake Forest University Health Sciences;   Wake Forest University;   University of Vermont;   National Institutes of Health (NIH)
    Recruiting
  • An Immunotherapy Study of Nivolumab Plus Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer
    NCT03873402
    Condition:   Renal Cell Carcinoma
    Interventions:   Biological: Nivolumab;   Biological: Ipilimumab;   Other: Ipilimumab placebo
    Sponsor:   Bristol-Myers Squibb
    Recruiting
  • Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer
    NCT03786094
    Conditions:   Metastatic Breast Cancer;   Locally Recurrent Breast Cancer
    Interventions:   Drug: Eribulin;   Drug: Balixafortide
    Sponsor:   Polyphor Ltd.
    Recruiting
  • The SNAP Trial: SPRINT® Peripheral Nerve Stimulation for the Treatment of Neuropathic Post-Amputation Pain
    NCT03783689
    Conditions:   Neuropathic Pain;   Amputation
    Intervention:   Device: SPRINT Peripheral Nerve Stimulation (PNS) System
    Sponsor:   SPR Therapeutics, Inc.
    Recruiting
  • A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND - OUTREACH)
    NCT03744676
    Conditions:   Lymphoma, Non-Hodgkin;   Lymphoma;   Lymphoma, B-Cell;   Lymphoma, Large B-Cell, Diffuse;   Neoplasms;   Neoplasms by Histologic Type;   Lymphoproliferative Disorders;   Lymphatic Diseases;   Immunoproliferative Disorders;   Immune System Disorder
    Intervention:   Biological: lisocabtagene maraleucel
    Sponsors:   Juno Therapeutics, Inc.;   Celgene Corporation
    Recruiting
  • Efficacy, Safety and Tolerability of AG013 in Oral Mucositis Compared to Placebo When Administered Three Times Per Day
    NCT03234465
    Condition:   Oral Mucositis
    Interventions:   Biological: AG013;   Other: Placebo
    Sponsor:   Oragenics, Inc.
    Recruiting
  • Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer
    NCT03088813
    Condition:   Small Cell Lung Cancer
    Interventions:   Drug: Irinotecan liposome injection;   Drug: Topotecan
    Sponsor:   Ipsen
    Recruiting
  • A Study of Risdiplam (RO7034067) in Adult and Pediatric Participants With Spinal Muscular Atrophy
    NCT03032172
    Condition:   Spinal Muscular Atrophy
    Intervention:   Drug: Risdiplam
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • Study of the Safety and Tolerability of AXA1665 in Subjects With Mild and Moderate Hepatic Insufficiency
    NCT04147936
    Condition:   Hepatic Insufficiency
    Interventions:   Dietary Supplement: AXA1665;   Dietary Supplement: Placebo
    Sponsor:   Axcella Health, Inc
    Recruiting
  • A Two-part Single- and Repeat-dose Study of CSJ137 in Anemic Chronic Hemodialysis Patients
    NCT02570854
    Condition:   Anemia, Iron-Deficiency
    Interventions:   Biological: CSJ137;   Drug: Placebo
    Sponsor:   Novartis Pharmaceuticals
    Recruiting
  • A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder
    NCT04041284
    Conditions:   Migraine;   Major Depressive Disorder
    Interventions:   Drug: Fremanezumab;   Drug: Placebo
    Sponsor:   Teva Branded Pharmaceutical Products, R&D Inc.
    Recruiting
  • Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease
    NCT03992066
    Condition:   Anemia Associated With Chronic Kidney Disease
    Interventions:   Drug: Vadadustat;   Drug: Darbepoetin alfa;   Drug: Epoetin alfa
    Sponsor:   Akebia Therapeutics
    Recruiting
  • Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)
    NCT03924856
    Condition:   Urinary Bladder Cancer, Muscle-invasive
    Interventions:   Drug: Pembrolizumab;   Drug: Gemcitabine;   Drug: Cisplatin;   Procedure: Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND]);   Drug: Placebo
    Sponsor:   Merck Sharp & Dohme Corp.
    Recruiting
  • Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL
    NCT02361346
    Conditions:   Non-Hodgkin's B-cell Lymphoma;   Leukemia, Lymphocytic, Chronic, B-Cell;   Small Lymphocytic Leukemia;   Diffuse Large B Cell Lymphoma;   Blood Cancer;   Hematological Malignancy
    Interventions:   Drug: MT-3724 Phase 1;   Drug: MT-3724 Phase 2
    Sponsor:   Molecular Templates, Inc.
    Recruiting
  • Apogee, A HeartWare HVAD Destination Product Surveillance Registry (PSR) Platform
    NCT03697980
    Condition:   Chronic Heart Failure
    Intervention:   Device: HeartWare Ventricular Assist Device
    Sponsor:   Medtronic Cardiac Rhythm and Heart Failure
    Recruiting
  • A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib
    NCT03535740
    Condition:   ALK-positive Advanced NSCLC
    Intervention:   Drug: Brigatinib
    Sponsor:   Ariad Pharmaceuticals
    Recruiting
  • Tavo and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Pembrolizumab or Nivolumab Treatment
    NCT03132675
    Condition:   Stage III/IV Melanoma
    Interventions:   Biological: tavokinogene telseplasmid;   Biological: Pembrolizumab;   Device: ImmunoPulse
    Sponsor:   OncoSec Medical Incorporated
    Recruiting
  • A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer
    NCT04060862
    Condition:   Breast Cancer
    Interventions:   Drug: Ipatasertib;   Drug: Placebo;   Drug: Palbociclib;   Drug: Fulvestrant
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas
    NCT03962543
    Conditions:   Plexiform Neurofibroma;   Neurofibromatosis Type 1 (NF1)
    Intervention:   Drug: PD-0325901 oral capsule
    Sponsor:   SpringWorks Therapeutics, Inc.
    Recruiting
  • A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma
    NCT03769090
    Condition:   Asthma
    Interventions:   Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg;   Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg;   Combination Product: Albuterol sulfate metered-dose inhaler 180 μg
    Sponsor:   Bond Avillion 2 Development LP
    Recruiting
  • Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung Cancer (NSCLC)(MK-7902-007/E7080-G000-314/LEAP-007)
    NCT03829332
    Condition:   Non-small Cell Lung Cancer
    Interventions:   Biological: Pembrolizumab;   Drug: Lenvatinib;   Drug: Placebo for lenvatinib
    Sponsors:   Merck Sharp & Dohme Corp.;   Eisai Inc.
    Recruiting
  • CMF Bone Stimulation as Adjunct to Surgical Treatment of Ankle Fractures
    NCT02688855
    Condition:   Bimalleolar Ankle Fractures
    Interventions:   Device: Active Combined Magnetic Field OL1000 Bone Growth Stimulator;   Device: Sham Combined Magnetic Field OL1000 Bone Growth Stimulator
    Sponsor:   Encore Medical, L.P.
    Recruiting
  • Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer
    NCT03822468
    Condition:   Breast Cancer
    Interventions:   Drug: Ribociclib;   Drug: Letrozole or Anastrozole;   Drug: Goserelin
    Sponsor:   Novartis Pharmaceuticals
    Recruiting
  • Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)
    NCT03797326
    Conditions:   Advanced Solid Tumors;   Triple Negative Breast Cancer;   Ovarian Cancer;   Gastric Cancer;   Colorectal Cancer;   Glioblastoma;   Biliary Tract Cancers
    Interventions:   Biological: Pembrolizumab;   Drug: Lenvatinib
    Sponsors:   Merck Sharp & Dohme Corp.;   Eisai Inc.
    Recruiting
  • A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease
    NCT03782376
    Condition:   Crohn Disease
    Interventions:   Drug: Ustekinumab approximately 6 mg/kg (IV);   Drug: Placebo (SC);   Drug: Placebo (IV);   Drug: Ustekinumab 90 mg (SC) Group 1;   Drug: Ustekinumab 90 mg (SC) Group 2
    Sponsor:   Janssen-Cilag Ltd.
    Recruiting
  • A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis
    NCT03653026
    Condition:   Ulcerative Colitis (UC)
    Interventions:   Drug: Upadacitinib (ABT-494);   Drug: Placebo
    Sponsor:   AbbVie
    Recruiting
  • A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer
    NCT03695380
    Condition:   OVARIAN CANCER
    Interventions:   Drug: Cobimetinib;   Drug: Niraparib;   Drug: Atezolizumab
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus
    NCT03517722
    Condition:   Lupus Erythematosus, Systemic
    Interventions:   Drug: Placebo;   Drug: Ustekinumab (approximately 6 mg/kg);   Drug: Ustekinumab 90 mg
    Sponsor:   Janssen Research & Development, LLC
    Recruiting
  • A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer
    NCT03561220
    Condition:   Prostate Cancer
    Interventions:   Radiation: Standard of Care IMRT (Photon);   Radiation: Standard of Care Proton Therapy;   Radiation: Proton Arm 1: Standard Proton Therapy;   Radiation: Proton Arm 2: Hypofractionated Proton Therapy
    Sponsors:   University of Florida;   Patient-Centered Outcomes Research Institute
    Recruiting
  • An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease
    NCT03467958
    Condition:   Crohn Disease
    Intervention:   Drug: Ozanimod
    Sponsor:   Celgene
    Recruiting
  • A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression
    NCT03543410
    Conditions:   Depressive Episode;   Bipolar 1 Depression
    Interventions:   Drug: SEP-4199 200 mg;   Drug: SEP-4199 400 mg;   Drug: Placebo
    Sponsor:   Sunovion
    Recruiting
  • A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease
    NCT03464097
    Condition:   Crohn Disease
    Interventions:   Drug: Ozanimod;   Other: Placebo
    Sponsor:   Celgene
    Recruiting
  • JUNIPER: A Phase 2 Study to Evaluate the Safety, Biological Activity, and PK of ND-L02-s0201 in Subjects With IPF
    NCT03538301
    Condition:   Idiopathic Pulmonary Fibrosis
    Interventions:   Drug: ND-L02-s0201;   Other: Other: Placebo
    Sponsor:   Nitto Denko Corporation
    Recruiting
  • BI655130 (SPESOLIMAB) Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis
    NCT03482635
    Condition:   Colitis, Ulcerative
    Interventions:   Drug: Spesolimab;   Drug: Placebo
    Sponsor:   Boehringer Ingelheim
    Recruiting
  • A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
    NCT03412565
    Condition:   Multiple Myeloma
    Interventions:   Drug: Daratumumab;   Drug: Bortezomib;   Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: Melphalan;   Drug: Prednisone;   Drug: Carfilzomib
    Sponsor:   Janssen Research & Development, LLC
    Recruiting
  • A Study of KZR-616 in Patients With Systemic Lupus Erythematosus With and Without Nephritis
    NCT03393013
    Conditions:   Systemic Lupus Erythematosus;   Lupus Nephritis
    Interventions:   Drug: KZR-616;   Drug: Placebo
    Sponsor:   Kezar Life Sciences, Inc.
    Recruiting
  • A Safety Extension Study of SHP647 in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
    NCT03283085
    Conditions:   Crohn's Disease;   Ulcerative Colitis
    Interventions:   Drug: 25 mg SHP647;   Drug: 75 mg SHP647
    Sponsor:   Shire
    Recruiting
  • A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in the Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors
    NCT04029688
    Conditions:   Acute Myeloid Leukemia (AML);   Acute Lymphoblastic Leukemia (ALL);   Neuroblastoma;   Solid Tumors
    Interventions:   Drug: Idasanutlin;   Drug: Venetoclax;   Drug: Cyclophosphamide;   Drug: Topotecan;   Drug: Fludarabine;   Drug: Cytarabine;   Drug: Intrathecal Chemotherapy
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma
    NCT04046939
    Conditions:   Eosinophilic Asthma;   Asthma
    Interventions:   Drug: low-dose dexpramipexole;   Drug: mid-dose dexpramipexole;   Drug: high-dose dexpramipexole;   Drug: placebo oral tablet
    Sponsor:   Knopp Biosciences
    Recruiting
  • A Study of the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease
    NCT03105128
    Condition:   Crohn's Disease
    Interventions:   Drug: placebo for risankizumab;   Drug: risankizumab IV;   Drug: risankizumab SC
    Sponsor:   AbbVie
    Recruiting
  • Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma
    NCT03108495
    Condition:   Cervical Carcinoma
    Interventions:   Biological: LN-145;   Biological: LN-145 + pembrolizumab
    Sponsor:   Iovance Biotherapeutics, Inc.
    Recruiting
  • Study of IMMU-132 in HR+/HER2- MBC (TROPICS-02)
    NCT03901339
    Condition:   Metastatic Breast Cancer
    Interventions:   Drug: Sacituzumab Govitecan;   Drug: Eribulin;   Drug: Capecitabine;   Drug: Gemcitabine;   Drug: Vinorelbine
    Sponsor:   Immunomedics, Inc.
    Recruiting
  • Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)
    NCT03881059
    Condition:   Active Psoriatic Arthritis
    Interventions:   Other: BMS-986165 Placebo;   Drug: BMS-986165 Dose A;   Drug: BMS-986165 Dose B;   Drug: Ustekinumab;   Other: Ustekinumab Placebo
    Sponsor:   Bristol-Myers Squibb
    Recruiting
  • Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease
    NCT03077412
    Condition:   Fistulizing Crohn's Disease
    Interventions:   Drug: Filgotinib;   Drug: Placebo to match filgotinib
    Sponsors:   Gilead Sciences;   Galapagos NV
    Recruiting
  • Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD)
    NCT03046056
    Condition:   Small Bowel Crohn's Disease
    Interventions:   Drug: Filgotinib;   Drug: Placebo to match filgotinib
    Sponsors:   Gilead Sciences;   Galapagos NV
    Recruiting
  • Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis
    NCT04186871
    Conditions:   Autoimmune Disorder;   Rheumatoid Arthritis;   Systemic Lupus Erythematosus;   Primary Sjögren's Syndrome
    Interventions:   Drug: branebrutinib;   Drug: abatacept;   Drug: branebrutinib placebo
    Sponsor:   Bristol-Myers Squibb
    Recruiting
  • A Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia
    NCT04172831
    Condition:   Fibromyalgia
    Interventions:   Drug: TNX-102 SL;   Drug: Placebo SL Tablet
    Sponsor:   Tonix Pharmaceuticals, Inc.
    Recruiting
  • A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)
    NCT04166773
    Condition:   Nonalcoholic Steatohepatitis
    Interventions:   Drug: Tirzepatide;   Drug: Placebo
    Sponsor:   Eli Lilly and Company
    Recruiting
  • Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial
    NCT03706833
    Conditions:   Degenerative Mitral Valve Disease;   Mitral Regurgitation;   Mitral Insufficiency;   Functional Mitral Regurgitation
    Interventions:   Device: Edwards PASCAL System;   Device: Abbott Mitraclip System
    Sponsor:   Edwards Lifesciences
    Recruiting
  • Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures
    NCT03678753
    Condition:   Primary Generalized Epilepsy
    Interventions:   Drug: Cenobamate;   Drug: Placebo
    Sponsor:   SK Life Science, Inc.
    Recruiting
  • A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis (UC)
    NCT02819635
    Condition:   Ulcerative Colitis (UC)
    Interventions:   Drug: Placebo;   Drug: Updacitinib (ABT-494)
    Sponsor:   AbbVie
    Recruiting
  • Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations
    NCT04053634
    Condition:   Chronic Obstructive Pulmonary Disease
    Interventions:   Biological: Benralizumab;   Biological: Placebo
    Sponsor:   AstraZeneca
    Recruiting
  • Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects
    NCT03631199
    Condition:   Non-small Cell Lung Cancer
    Interventions:   Drug: canakinumab;   Drug: canakinumab matching placebo;   Drug: pembrolizumab;   Drug: carboplatin;   Drug: cisplatin;   Drug: paclitaxel;   Drug: nab-paclitaxel;   Drug: pemetrexed
    Sponsor:   Novartis Pharmaceuticals
    Recruiting
  • Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder
    NCT04044664
    Condition:   Post-Traumatic Stress Disorder
    Interventions:   Drug: Placebo oral capsule;   Drug: NYX-783
    Sponsors:   Aptinyx;   Premier Research Group plc;   Massachusetts General Hospital
    Recruiting
  • Tezepelumab COPD Exacerbation Study
    NCT04039113
    Condition:   Chronic Obstructive Pulmonary Disease (COPD)
    Interventions:   Biological: Tezepelumab;   Other: Placebo
    Sponsors:   AstraZeneca;   Amgen
    Recruiting
  • A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
    NCT04035005
    Condition:   Multiple Sclerosis, Primary Progressive
    Interventions:   Drug: Ocrelizumab;   Drug: Placebo
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH.
    NCT04019561
    Conditions:   Non-alcoholic Fatty Liver Disease (NAFLD);   Non-alcoholic Steatohepatitis (NASH)
    Interventions:   Drug: MEDI0382 high dose;   Drug: Placebo for MEDI0382 high dose;   Drug: MEDI0382 low dose;   Drug: Placebo for MEDI0382 low dose
    Sponsor:   MedImmune LLC
    Recruiting
  • A Study to Evaluate Next-Dose Transition From Zolpidem to Lemborexant (LEM) for the Treatment of Insomnia
    NCT04009577
    Condition:   Insomnia
    Interventions:   Drug: LEM 5 mg;   Drug: LEM 10 mg
    Sponsor:   Eisai Inc.
    Recruiting
  • A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Subjects With Major Depressive Disorder
    NCT04007367
    Condition:   Major Depressive Disorder
    Interventions:   Drug: SAGE-217;   Drug: Placebo
    Sponsor:   Sage Therapeutics
    Recruiting
  • A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2
    NCT04003142
    Condition:   Hot Flashes
    Interventions:   Drug: fezolinetant;   Drug: placebo
    Sponsor:   Astellas Pharma Global Development, Inc.
    Recruiting
  • Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
    NCT04000009
    Condition:   Adjunctive Treatment of Major Depressive Disorder
    Intervention:   Drug: Pimavanserin
    Sponsor:   ACADIA Pharmaceuticals Inc.
    Recruiting
  • Randomized Trial of the Neochord DS1000 System Versus Open Surgical Repair
    NCT02803957
    Condition:   Mitral Valve Insufficiency
    Interventions:   Device: NeoChord DS1000;   Device: Surgical Mitral Valve Repair
    Sponsor:   NeoChord
    Recruiting
  • Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors
    NCT02717507
    Condition:   Cancer Survivor
    Interventions:   Drug: Carvedilol;   Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study;   Other: Pharmacological Study;   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment (CLARITY-2)
    NCT03968159
    Condition:   Adjunctive Treatment of Major Depressive Disorder
    Interventions:   Drug: Pimavanserin;   Drug: Placebo
    Sponsor:   ACADIA Pharmaceuticals Inc.
    Recruiting
  • A Study to Test the Effectiveness and Safety of Fremanezumab on Patients With Fibromyalgia
    NCT03965091
    Condition:   Fibromyalgia
    Interventions:   Drug: Fremanezumab - Dose A;   Drug: Fremanezumab - Dose B;   Drug: Placebo
    Sponsor:   Teva Branded Pharmaceutical Products, R&D Inc.
    Recruiting
  • De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
    NCT03952585
    Conditions:   Basaloid Squamous Cell Carcinoma;   Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Oropharyngeal Squamous Cell Carcinoma;   Papillary Squamous Cell Carcinoma;   Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
    Interventions:   Drug: Cisplatin;   Radiation: Image Guided Radiation Therapy;   Radiation: Intensity-Modulated Radiation Therapy;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Recruiting
  • Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])
    NCT03517449
    Condition:   Endometrial Neoplasms
    Interventions:   Drug: Pembrolizumab;   Drug: Lenvatinib;   Drug: Paclitaxel;   Drug: Doxorubicin
    Sponsors:   Eisai Inc.;   Merck Sharp & Dohme Corp.
    Recruiting

Popular Now

  • Privacy Policy
  • Ad and Cookie Policy
  • Infringement Policy
  • Terms of Use
  • Email Policy
  • Contact Us
  • Post Clinical Trials
  • Join Clinical Trials
  • Volunteer Login
  • Recruiters Login
  • Frequently Asked Questions
  • Blog
  • Find Clinical Trials
  • Find Volunteers
  • Trials by Category
  • Trials by Location
  • Volunteers by Category
  • Volunteers by Location
All clinical trials are registered and certified with clinicaltrials.gov. Data via U.S. National Library of Medicine,U.S. National Institutes of Health, U.S. Department of Health & Human Services. JoinClinicaltrials.com (Aunica Media llc) is a free resource that provides individuals and companies with information regarding clinical trials that are being conducted nationwide. Aunica Media llc does not conduct clinical trials nor endorses them. Please consult your doctor or physician before participating. And Ye shall know the truth, and the truth shall make you free
©2001-2019 Aunica Media LLC